Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Alkermes (ALKS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Alkermes is one of 929 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks ...

Group 1 - The top gainers among Chinese concept stocks include: Chuangzhi Global Technology up 60.10%, Ping An Biopharmaceutical up 21.84%, Epsium Enterprise up 21.42%, Agencia Comercial Spirits up 18.34%, and CASI Pharmaceuticals up 17.65% [1] - Chuangzhi Global Technology (CGTL) closed at 2.530 with a significant increase of 118.10%, gaining 1.370 with a trading volume of 54.5447 million [1] - Ping An Biopharmaceutical (PASW) reached a price of 0.6183, reflecting a rise of 33.95%, with an increase of 0.1567 and a trading volume of 599,000 [1] Group 2 - Epsium Enterprise (EPSM) saw its stock price rise to 2.730, marking an increase of 28.17%, with a gain of 0.600 and a trading volume of 397,900 [1] - Agencia Comercial Spirits (AGCC) closed at 13.230, up 25.28%, gaining 2.670 with a trading volume of 1,000,600 [1] - CASI Pharmaceuticals (CASI) ended at 1.0650, reflecting a rise of 23.26%, with an increase of 0.2010 and a trading volume of 124,400 [1]

Core Viewpoint - CASI Pharmaceuticals has received an extension from the Nasdaq Hearings Panel to continue its listing, contingent upon regaining compliance with the Market Value of Listed Securities Rule by February 17, 2026 [1] Company Developments - The Panel's decision was influenced by recent strategic appointments, including a new Chief Executive Officer and a Non-Executive Chairman [1] - The company is focusing on the development of CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [1] - CASI is executing a convertible note purchase agreement and is pursuing additional financing initiatives [1] - There are plans for the divestiture of assets in China as part of the company's strategic realignment [1]

Core Viewpoint - CASI Pharmaceuticals has announced a $20 million investment through a convertible note purchase agreement to fund a Phase 1 study in China for renal allograft antibody-mediated rejection (AMR) and to develop a stable, high concentration protein solution for subcutaneous formulation [1][5]. Group 1: Investment Details - The investment will be made in tranches and is subject to multiple closings, contingent on the Purchaser's satisfaction with the Company's business results and financial status [2]. - Each convertible note will mature in 36 months, bearing an interest rate of 12% per annum, and can be converted into ordinary shares at a specified conversion price [3]. Group 2: Company Overview - CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [4][5]. - CID-103 has shown promising pre-clinical efficacy and clinical safety, and the company has received FDA IND clearance for a Phase 1 study in the U.S. [5].

Core Insights - CASI Pharmaceuticals, Inc. is developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [1] - The company presented data from a Phase 1 open-label study of CID-103 for immune thrombocytopenia (ITP) at the 67th American Society of Hematology Annual Meeting [1] Study Details - The Phase 1 study involved adult patients with ITP and utilized a dose escalation approach with intravenous infusions of CID-103 [1] - Patients were assigned to sequential dose-escalating cohorts receiving CID-103 at doses of 30 mg (n=1), 150 mg (n=1), 300 mg (n=3), 600 mg (n=3), and 900 mg (n=3) [1] - A priming dose of CID-103 was administered prior to the cohort dose, either at 30 mg or 150 mg [1]

Core Viewpoint - CASI Pharmaceuticals has appointed James Huang as Non-Executive Chairman of the Board, effective November 17, 2025, marking a significant leadership transition within the company [1] Group 1: Leadership Changes - James Huang, previously an independent board member, has been unanimously voted in as Non-Executive Chairman of CASI Pharmaceuticals [1] - Dr. Wei-Wu He will step down from his role as Executive Chairman but will continue to serve as a member of the Board of Directors [1]

Financial Performance - Revenues for Q3 2025 were $3.1 million, a 60% decrease from $7.8 million in Q3 2024, primarily due to estimated goods returns for EVOMELA[8] - Revenues for Q3 2025 decreased to $3,075,000 from $7,793,000 in Q3 2024, representing a decline of 60.5%[24] - Net loss for Q3 2025 was $10.9 million, compared to $8.4 million in Q3 2024, attributed to the decrease in revenues[11] - Net loss for Q3 2025 increased to $10,883,000 compared to a net loss of $8,395,000 in Q3 2024, an increase of 29.7%[24] - Net loss per share (basic and diluted) for Q3 2025 was $(0.67), compared to $(0.55) in Q3 2024, indicating a worsening loss per share[24] - Total comprehensive loss for the nine months ended September 2025 was $35,512,000, compared to $25,156,000 in the same period of 2024, an increase of 41.1%[24] Expenses - Cost of revenue for Q3 2025 was $2.4 million, a 35% decrease compared to $3.7 million in the same period last year[9] - General and administrative expenses for Q3 2025 were $4.9 million, a 14% decrease from $5.7 million in Q3 2024[10] - Research and development expenses for Q3 2025 were $1.4 million, stable compared to $1.5 million in the same period last year[9] - Research and development expenses for the nine months ended September 2025 were $5,073,000, slightly down from $5,251,000 in the same period of 2024, a decrease of 3.4%[24] - General and administrative expenses for the nine months ended September 2025 increased to $18,709,000 from $16,456,000 in 2024, an increase of 7.6%[24] - Selling and marketing expenses for the nine months ended September 2025 were $13,793,000, up from $13,069,000 in 2024, an increase of 5.5%[24] - Total operating expenses for Q3 2025 were $11,383,000, a reduction from $12,509,000 in Q3 2024, reflecting a decrease of 9.0%[24] Cash and Financing - As of September 30, 2025, cash and cash equivalents were $4.7 million, down from $13.5 million as of December 31, 2024[11] - The company raised approximately $5.7 million from an at-the-market facility during Q3 2025[7] Research and Development - CID-103 is in a Phase 1 dose-escalation study for immune thrombocytopenia (ITP), with dosing at the highest dose of 900 mg ongoing[6] - The company plans to present results of the ongoing Phase 1 study of CID-103 at the ASH 2025 meeting on December 7, 2025[3] Business Strategy - The company is targeting completion of the divestiture of its China business in Q2 2026[6] Shareholder Information - The weighted average number of ordinary shares outstanding increased to 16,049,321 in Q3 2025 from 15,294,393 in Q3 2024, an increase of 4.9%[24]

Core Viewpoint - CASI Pharmaceuticals, Inc. is advancing its CID-103 clinical program, targeting organ transplant rejection and autoimmune diseases, with a focus on renal allograft antibody mediated rejection (AMR) [1] Financial Results - The company reported its business and financial results for the third quarter ended September 30, 2025 [1] Clinical Development - CID-103 is positioned as a potential best-in-class anti-CD38 monoclonal antibody [1] - The clinical program for CID-103 is first being conducted in the U.S. under an already approved IND, followed by a regulatory package that has been accepted and is under review in China [1]

Core Viewpoint - CASI Pharmaceuticals has received a delisting determination from Nasdaq due to its market value of listed securities falling below the minimum requirement of $35 million for 30 consecutive trading days, and the company has appealed this decision to regain compliance [2][3]. Company Update - CASI Pharmaceuticals, Inc. is focused on developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases [5][6]. - The company was notified on May 5, 2025, that it did not comply with Nasdaq Listing Rule 5550(b)(2) due to its market value falling below the required threshold [2]. - CASI has appealed the delisting determination and requested a hearing to present a plan for regaining compliance, which will temporarily stay the suspension of its securities [3][4]. Product Development - CID-103 is a fully human IgG1 monoclonal antibody that has shown promising pre-clinical efficacy and clinical safety compared to other anti-CD38 monoclonal antibodies [6]. - The company has received FDA IND clearance to conduct a Phase 1 study in the U.S. for renal allograft antibody-mediated rejection, with plans to enroll the first patient in the first quarter of 2026 [6]. - CASI is also actively recruiting patients for an ongoing Phase 1 study in immune thrombocytopenia (ITP) and is exploring technologies for developing a stable, high concentration protein solution for subcutaneous injection [6].

Core Insights - CASI Pharmaceuticals, Inc. is developing CID-103, a potential best-in-class anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases [1] - The company announced that data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP) will be presented at the 67th American Society of Hematology Annual Meeting [1] Company Overview - CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for serious diseases [1] - CID-103 is being investigated for its efficacy in treating patients with immune thrombocytopenia, a condition characterized by low platelet counts [1] Study Details - The Phase 1 study is a dose-escalation and safety study followed by a randomized, open-label, parallel-arm multi-dose study [1] - The study evaluates the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia [1] - The presentation will take place during the session named 311 at the annual meeting scheduled for December 6-9, 2025, in Orlando, Florida [1]